Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

listen audio

Study Justification:
– In an era of shifting global agendas and expanded emphasis on non-communicable diseases and injuries along with communicable diseases, sound evidence on trends by cause at the national level is essential.
– The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides a systematic scientific assessment of published, publicly available, and contributed data on incidence, prevalence, and mortality for a mutually exclusive and collectively exhaustive list of diseases and injuries.
Study Highlights:
– Global health has steadily improved over the past 30 years as measured by age-standardized DALY rates.
– The absolute number of DALYs has remained stable after taking into account population growth and aging.
– The pace of decline in global age-standardized DALY rates has accelerated in age groups younger than 50 years since 2010.
– Six infectious diseases were among the top ten causes of DALYs in children younger than 10 years in 2019.
– In adolescents aged 10-24 years, three injury causes were among the top causes of DALYs.
– Ischemic heart disease and stroke were the top-ranked causes of DALYs in older age groups.
– There has been a marked shift towards a greater proportion of burden due to YLDs from non-communicable diseases and injuries since 1990.
– Decreases in age-standardized DALY rates have accelerated over the past decade in countries at the lower end of the Socio-demographic Index (SDI) range, while improvements have started to stagnate or even reverse in countries with higher SDI.
Study Recommendations:
– Greater research and development investment is needed to identify new, more effective intervention strategies as disability becomes an increasingly large component of disease burden and health expenditure.
– Policy makers need to anticipate the demands on health services to deal with disabling outcomes, which increase with age due to a rapidly aging global population.
– Regular reporting on population health in detail and by underlying cause is necessary to help decision makers identify success stories of disease control and opportunities for improvement.
Key Role Players:
– Researchers and scientists involved in the Global Burden of Disease Study
– Policy makers and government officials responsible for healthcare planning and decision making
– Health organizations and institutions
– Non-governmental organizations (NGOs) working in the field of public health
– Healthcare professionals and practitioners
– Data analysts and statisticians
Cost Items for Planning Recommendations:
– Research and development funding for identifying new intervention strategies
– Healthcare infrastructure and facilities
– Training and capacity building for healthcare professionals
– Data collection and analysis
– Health education and awareness campaigns
– Implementation of healthcare policies and programs
– Monitoring and evaluation of interventions
– Collaboration and coordination between different stakeholders

The strength of evidence for this abstract is 9 out of 10.
The evidence in the abstract is strong because it is based on the Global Burden of Disease Study (GBD), which provides a systematic scientific assessment of published, publicly available, and contributed data on incidence, prevalence, and mortality for a comprehensive list of diseases and injuries. The study uses a wide range of data sources and employs rigorous methods, including Bayesian meta-regression modeling. The findings are presented in a clear and detailed manner, and the study complies with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) statement. To improve the evidence, it would be helpful to provide more specific information on the data sources used and the statistical methods employed.

Background: In an era of shifting global agendas and expanded emphasis on non-communicable diseases and injuries along with communicable diseases, sound evidence on trends by cause at the national level is essential. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides a systematic scientific assessment of published, publicly available, and contributed data on incidence, prevalence, and mortality for a mutually exclusive and collectively exhaustive list of diseases and injuries. Methods: GBD estimates incidence, prevalence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) due to 369 diseases and injuries, for two sexes, and for 204 countries and territories. Input data were extracted from censuses, household surveys, civil registration and vital statistics, disease registries, health service use, air pollution monitors, satellite imaging, disease notifications, and other sources. Cause-specific death rates and cause fractions were calculated using the Cause of Death Ensemble model and spatiotemporal Gaussian process regression. Cause-specific deaths were adjusted to match the total all-cause deaths calculated as part of the GBD population, fertility, and mortality estimates. Deaths were multiplied by standard life expectancy at each age to calculate YLLs. A Bayesian meta-regression modelling tool, DisMod-MR 2.1, was used to ensure consistency between incidence, prevalence, remission, excess mortality, and cause-specific mortality for most causes. Prevalence estimates were multiplied by disability weights for mutually exclusive sequelae of diseases and injuries to calculate YLDs. We considered results in the context of the Socio-demographic Index (SDI), a composite indicator of income per capita, years of schooling, and fertility rate in females younger than 25 years. Uncertainty intervals (UIs) were generated for every metric using the 25th and 975th ordered 1000 draw values of the posterior distribution. Findings: Global health has steadily improved over the past 30 years as measured by age-standardised DALY rates. After taking into account population growth and ageing, the absolute number of DALYs has remained stable. Since 2010, the pace of decline in global age-standardised DALY rates has accelerated in age groups younger than 50 years compared with the 1990–2010 time period, with the greatest annualised rate of decline occurring in the 0–9-year age group. Six infectious diseases were among the top ten causes of DALYs in children younger than 10 years in 2019: lower respiratory infections (ranked second), diarrhoeal diseases (third), malaria (fifth), meningitis (sixth), whooping cough (ninth), and sexually transmitted infections (which, in this age group, is fully accounted for by congenital syphilis; ranked tenth). In adolescents aged 10–24 years, three injury causes were among the top causes of DALYs: road injuries (ranked first), self-harm (third), and interpersonal violence (fifth). Five of the causes that were in the top ten for ages 10–24 years were also in the top ten in the 25–49-year age group: road injuries (ranked first), HIV/AIDS (second), low back pain (fourth), headache disorders (fifth), and depressive disorders (sixth). In 2019, ischaemic heart disease and stroke were the top-ranked causes of DALYs in both the 50–74-year and 75-years-and-older age groups. Since 1990, there has been a marked shift towards a greater proportion of burden due to YLDs from non-communicable diseases and injuries. In 2019, there were 11 countries where non-communicable disease and injury YLDs constituted more than half of all disease burden. Decreases in age-standardised DALY rates have accelerated over the past decade in countries at the lower end of the SDI range, while improvements have started to stagnate or even reverse in countries with higher SDI. Interpretation: As disability becomes an increasingly large component of disease burden and a larger component of health expenditure, greater research and development investment is needed to identify new, more effective intervention strategies. With a rapidly ageing global population, the demands on health services to deal with disabling outcomes, which increase with age, will require policy makers to anticipate these changes. The mix of universal and more geographically specific influences on health reinforces the need for regular reporting on population health in detail and by underlying cause to help decision makers to identify success stories of disease control to emulate, as well as opportunities to improve. Funding: Bill & Melinda Gates Foundation.

The general approach to estimating causes of death and disease incidence and prevalence for GBD 2019 is the same as for GBD 2017.2, 3 Appendix 1 provides details on the methods used to model each disease and injury. Here, we provide an overview of the methods, with an emphasis on the main methodology changes since GBD 2017. For each iteration of GBD, the estimates for the whole time series are updated on the basis of addition of new data and change in methods where appropriate. Thus, the GBD 2019 results supersede those from previous rounds of GBD. GBD 2019 complies with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) statement (appendix 1 section 1.4).8 Analyses were completed with Python version 3.6.2, Stata version 13, and R version 3.5.0. Statistical code used for GBD estimation is publicly available online. GBD 2019 estimated each epidemiological quantity of interest—incidence, prevalence, mortality, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs)—for 23 age groups; males, females, and both sexes combined; and 204 countries and territories that were grouped into 21 regions and seven super-regions. For GBD 2019, nine countries and territories (Cook Islands, Monaco, San Marino, Nauru, Niue, Palau, Saint Kitts and Nevis, Tokelau, and Tuvalu) were added, such that the GBD location hierarchy now includes all WHO member states. GBD 2019 includes subnational analyses for Italy, Nigeria, Pakistan, the Philippines, and Poland, and 16 countries previously estimated at subnational levels (Brazil, China, Ethiopia, India, Indonesia, Iran, Japan, Kenya, Mexico, New Zealand, Norway, Russia, South Africa, Sweden, the UK, and the USA). All subnational analyses are at the first level of administrative organisation within each country except for New Zealand (by Māori ethnicity), Sweden (by Stockholm and non-Stockholm), the UK (by local government authorities), and the Philippines (by province). In this publication, we present subnational estimates for Brazil, India, Indonesia, Japan, Kenya, Mexico, Sweden, the UK, and the USA; given space constraints, these results are presented in appendix 2. At the most detailed spatial resolution, we generated estimates for 990 locations. The GBD diseases and injuries analytical framework generated estimates for every year from 1990 to 2019. Diseases and injuries were organised into a levelled cause hierarchy from the three broadest causes of death and disability at Level 1 to the most specific causes at Level 4. Within the three Level 1 causes—communicable, maternal, neonatal, and nutritional diseases; non-communicable diseases; and injuries—there are 22 Level 2 causes, 174 Level 3 causes, and 301 Level 4 causes (including 131 Level 3 causes that are not further disaggregated at Level 4; see appendix 1 sections 3.4 and 4.12 for the full list of causes). 364 total causes are non-fatal and 286 are fatal. For GBD 2019, 12 new causes were added to the modelling framework: pulmonary arterial hypertension, eye cancer, soft tissue and other extraosseous sarcomas, malignant neoplasm of bone and articular cartilage, and neuroblastoma and other peripheral nervous cell tumours at Level 3, and hepatoblastoma, Burkitt lymphoma, other non-Hodgkin lymphoma, retinoblastoma, other eye cancers, and two sites of osteoarthritis (hand and other joints) at Level 4. The GBD estimation process is based on identifying multiple relevant data sources for each disease or injury including censuses, household surveys, civil registration and vital statistics, disease registries, health service use, air pollution monitors, satellite imaging, disease notifications, and other sources. Each of these types of data are identified from systematic review of published studies, searches of government and international organisation websites, published reports, primary data sources such as the Demographic and Health Surveys, and contributions of datasets by GBD collaborators. 86 249 sources were used in this analysis, including 19 354 sources reporting deaths, 31 499 reporting incidence, 19 773 reporting prevalence, and 26 631 reporting other metrics. Each newly identified and obtained data source is given a unique identifier by a team of librarians and included in the Global Health Data Exchange (GHDx). The GHDx makes publicly available the metadata for each source included in GBD as well as the data, where allowed by the data provider. Readers can use the GHDx source tool to identify which sources were used for estimating any disease or injury outcome in any given location. A crucial step in the GBD analytical process is correcting for known bias by redistributing deaths from unspecified codes to more specific disease categories, and by adjusting data with alternative case definitions or measurement methods to the reference method. We highlight several major changes in data processing that in some cases have affected GBD results. Vital registration with medical certification of cause of death is a crucial resource for the GBD cause of death analysis in many countries. Cause of death data obtained using various revisions of the International Classification of Diseases and Injuries (ICD)9 were mapped to the GBD cause list. Many deaths, however, are assigned to causes that cannot be the underlying cause of death (eg, cardiopulmonary failure) or are inadequately specified (eg, injury from undetermined intent). These deaths were reassigned to the most probable underlying causes of death as part of the data processing for GBD. Redistribution algorithms can be divided into three categories: proportionate redistribution, fixed proportion redistribution based on published studies or expert judgment, or statistical algorithms. For GBD 2019, data for 116 million deaths attributed to multiple causes were analysed to produce more empirical redistribution algorithms for sepsis,10 heart failure, pulmonary embolism, acute kidney injury, hepatic failure, acute respiratory failure, pneumonitis, and five intermediate causes (hydrocephalus, toxic encephalopathy, compression of brain, encephalopathy, and cerebral oedema) in the central nervous system. To redistribute unspecified injuries, we used a method similar to that of intermediate cause redistribution, using the pattern of the nature of injury codes in the causal chain where the ICD codes X59 (“exposure to unspecified factor”) and Y34 (“unspecified event, undetermined intent”) and GBD injury causes were the underlying cause of death. These new algorithms led to important changes in the causes to which these intermediate outcomes were redistributed. Additionally, data on deaths from diabetes and stroke lack the detail on subtype in many countries; we ran regressions on vital registration data with at least 50% of deaths coded specifically to type 1 or 2 diabetes and ischaemic, haemorrhagic, or subarachnoid stroke to predict deaths by these subtypes when these were coded to unspecified diabetes or stroke. In previous cycles of GBD, data reported using alternative case definitions or measurement methods were corrected to the reference definition or measurement method primarily as part of the Bayesian meta-regression models. For example, in DisMod-MR, the population data were simultaneously modelled as a function of country covariates for variation in true rates and as a function of indicator variables capturing alternative measurement methods. To enhance transparency and to standardise and improve methods in GBD 2019, we estimated correction factors for alternative case definitions or measurement methods using network meta-regression, including only data where two methods were assessed in the same location–time period or in the exact same population. This included validation studies where two methods had been compared in populations that were not necessarily random samples of the general population. Details on the correction factors from alternative to reference measurement methods are provided in appendix 1 (section 4.4.2). Clinical informatics data include inpatient admissions, outpatient (including general practitioner) visits, and health insurance claims. Several data processing steps were undertaken. Inpatient hospital data with a single diagnosis only were adjusted to account for non-primary diagnoses as well as outpatient care. For each GBD cause that used clinical data, ratios of non-primary to primary diagnosis rates were extracted from claims in the USA, Taiwan (province of China), New Zealand, and the Philippines, as well as USA Healthcare Cost and Utilization Project inpatient data. Ratios of outpatient to inpatient care for each cause were extracted from claims data from the USA and Taiwan (province of China). The log of the ratios for each cause were modelled by age and sex using MR-BRT (Meta-Regression-Bayesian Regularised Trimmed), the Bayesian meta-regression tool. To account for the incomplete health-care access in populations where not every person with a disease or injury would be accounted for in administrative clinical records, we transformed the adjusted admission rates using a scalar derived from the Healthcare Access and Quality Index.11 We used this approach to produce adjusted, standardised clinical data inputs. More details are provided in appendix 1 (section 4.3). For most diseases and injuries, processed data are modelled using standardised tools to generate estimates of each quantity of interest by age, sex, location, and year. There are three main standardised tools: Cause of Death Ensemble model (CODEm), spatiotemporal Gaussian process regression (ST-GPR), and DisMod-MR. Previous publications2, 3, 12 and the appendix provide more details on these general GBD methods. Briefly, CODEm is a highly systematised tool to analyse cause of death data using an ensemble of different modelling methods for rates or cause fractions with varying choices of covariates that perform best with out-of-sample predictive validity testing. DisMod-MR is a Bayesian meta-regression tool that allows evaluation of all available data on incidence, prevalence, remission, and mortality for a disease, enforcing consistency between epidemiological parameters. ST-GPR is a set of regression methods that borrow strength between locations and over time for single metrics of interest, such as risk factor exposure or mortality rates. In addition, for select diseases, particularly for rarer outcomes, alternative modelling strategies have been developed, which are described in appendix 1 (section 3.2). In GBD 2019, we designated a set of standard locations that included all countries and territories as well as the subnational locations for Brazil, China, India, and the USA. Coefficients of covariates in the three main modelling tools were estimated for these standard locations only—ie, we ignored data from subnational locations other than for Brazil, China, India, and the USA (appendix 1 section 1.1). Using this set of standard locations will prevent changes in regression coefficients from one GBD cycle to the next that are solely due to the addition of new subnational units in the analysis that might have lower quality data or small populations (appendix 1 section 1.1). Changes to CODEm for GBD 2019 included the addition of count models to the model ensemble for rarer causes. We also modified DisMod-MR priors to effectively increase the out-of-sample coverage of uncertainty intervals (UIs) as assessed in simulation testing (appendix 1 section 4.5). For the cause Alzheimer’s disease and other dementias, we changed the method of addressing large variations between locations and over time in the assignment of dementia as the underlying cause of death. Based on a systematic review of published cohort studies, we estimated the relative risk of death in individuals with dementia. We identified the proportion of excess deaths in patients with dementia where dementia is the underlying cause of death as opposed to a correlated risk factor (appendix 1 section 2.6.2). We changed the strategy of modelling deaths for acute hepatitis A, B, C, and E from a natural history model relying on inpatient case fatality rates to CODEm models after predicting type-specific acute hepatitis deaths from vital registration data with specified hepatitis type. DisMod-MR was used to estimate deaths from three outcomes (dementia, Parkinson’s, and atrial fibrillation), and to determine the proportions of deaths by underlying aetiologies of cirrhosis, liver cancer, and chronic kidney disease deaths. The Socio-demographic Index (SDI) is a composite indicator of a country’s lag-distributed income per capita, average years of schooling, and the fertility rate in females under the age of 25 years (appendix 1 section 6).13 For changes over time, we present annualised rates of change as the difference in the natural log of the values at the start and end of the time interval divided by the number of years in the interval. We examine the relationship between SDI and the annualised rate of change in age-standardised DALY rates for all causes, apart from HIV/AIDS, natural disasters, and war and conflict, by country or territory, for the time periods 1990–2010 and 2010–19. We deliberately subtracted out DALYs due to HIV/AIDS because their magnitude in some parts of the world would have obscured the trends in all other causes; we also subtracted out DALY rates from natural disasters and war and conflict to avoid trends in disease burden in some countries being dominated by these sudden and dramatic changes. As a measure of the epidemiological transition, we present the ratio of YLDs due to non-communicable diseases and injuries, and due to total burden in DALYs. We present 95% UIs for every metric based on the 25th and 975th ordered values of 1000 draws of the posterior distribution. The funders of this study had no role in study design, data collection, data analysis, data interpretation, or the writing of the report. The corresponding author had full access to the data in the study and final responsibility for the decision to submit for publication.

Based on the provided information, it is difficult to directly identify specific innovations for improving access to maternal health. However, some potential recommendations for innovations in this area could include:

1. Telemedicine and mobile health (mHealth) solutions: These technologies can be used to provide remote consultations, prenatal care, and postnatal support to pregnant women in areas with limited access to healthcare facilities.

2. Community-based interventions: Implementing community health workers or midwives who can provide essential maternal health services, education, and support to women in rural or underserved areas.

3. Mobile clinics: Utilizing mobile clinics to bring maternal health services, including prenatal care, vaccinations, and screenings, to remote or marginalized communities.

4. Digital health records: Implementing electronic health records systems that can securely store and share maternal health information, ensuring continuity of care and reducing duplication of tests and procedures.

5. Innovative transportation solutions: Developing transportation networks or systems specifically designed to transport pregnant women to healthcare facilities in a timely and safe manner.

6. Task-shifting and skill-sharing: Training and empowering non-specialist healthcare providers, such as nurses or community health workers, to perform certain maternal health services, thereby increasing access to care.

7. Public-private partnerships: Collaborating with private sector organizations to leverage their resources, expertise, and technology to improve access to maternal health services.

8. Financial innovations: Developing innovative financing models, such as microinsurance or community-based savings schemes, to make maternal health services more affordable and accessible to low-income women.

9. Health education and awareness campaigns: Implementing targeted campaigns to raise awareness about the importance of maternal health, promote healthy behaviors, and address cultural or social barriers to accessing care.

10. Quality improvement initiatives: Implementing evidence-based guidelines and protocols, as well as monitoring and evaluation systems, to ensure the provision of high-quality maternal health services.

It is important to note that the specific innovations and recommendations should be tailored to the local context and needs of the target population.
AI Innovations Description
The provided text is a description of the methods and findings of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) for the year 2019. It outlines the approach used to estimate causes of death and disease incidence and prevalence, as well as the main changes in methodology since the previous GBD study in 2017.

While the description does not specifically provide a recommendation for improving access to maternal health, it does highlight the importance of research and development investment to identify new and more effective intervention strategies. It emphasizes the need for regular reporting on population health in detail and by underlying cause to help decision-makers identify successful disease control measures to replicate and opportunities for improvement.

Based on this information, a potential recommendation to improve access to maternal health could be to invest in research and development to identify innovative interventions that address the specific challenges and barriers faced by pregnant women and new mothers. This could involve developing new technologies, improving healthcare infrastructure, and implementing targeted interventions to address maternal health issues in different regions and populations. Additionally, regular monitoring and reporting on maternal health outcomes and interventions can help identify areas of success and areas that require further attention and improvement.
AI Innovations Methodology
To improve access to maternal health, here are some potential recommendations:

1. Telemedicine: Implementing telemedicine programs can provide remote access to healthcare professionals for prenatal care, postpartum support, and consultations. This can be especially beneficial for women in rural or underserved areas who may have limited access to healthcare facilities.

2. Mobile health (mHealth) applications: Developing mobile applications that provide educational resources, appointment reminders, and personalized health information can empower pregnant women to take control of their health and make informed decisions. These apps can also facilitate communication between healthcare providers and patients.

3. Community health workers: Training and deploying community health workers can help bridge the gap between healthcare facilities and pregnant women in remote areas. These workers can provide basic prenatal care, health education, and referrals to appropriate healthcare services.

4. Transportation support: Lack of transportation can be a significant barrier to accessing maternal healthcare, especially in rural areas. Providing transportation support, such as subsidized or free transportation services, can ensure that pregnant women can reach healthcare facilities in a timely manner.

5. Financial incentives: Offering financial incentives, such as cash transfers or vouchers, can encourage pregnant women to seek prenatal care and deliver in healthcare facilities. This can help reduce financial barriers and increase access to quality maternal healthcare.

To simulate the impact of these recommendations on improving access to maternal health, a methodology could include the following steps:

1. Define the target population: Identify the specific population group that will be the focus of the simulation, such as pregnant women in a particular region or country.

2. Collect baseline data: Gather relevant data on the current state of maternal health access in the target population, including indicators such as prenatal care coverage, facility-based deliveries, and maternal mortality rates.

3. Define the intervention scenarios: Develop different scenarios that represent the implementation of the recommended innovations. For example, one scenario could involve the introduction of telemedicine services, while another scenario could focus on the deployment of community health workers.

4. Model the impact: Use mathematical modeling techniques to estimate the potential impact of each intervention scenario on key outcome measures, such as increased prenatal care utilization or reduced maternal mortality rates. This can involve analyzing historical data, conducting surveys, and applying statistical models.

5. Assess feasibility and cost-effectiveness: Evaluate the feasibility and cost-effectiveness of each intervention scenario by considering factors such as infrastructure requirements, resource allocation, and potential barriers to implementation.

6. Compare and prioritize interventions: Compare the projected impact and feasibility of each intervention scenario to determine which recommendations are most likely to have the greatest positive effect on improving access to maternal health. Prioritize interventions based on their potential impact and feasibility.

7. Monitor and evaluate: Implement the recommended interventions and establish a monitoring and evaluation framework to track progress and assess the actual impact on maternal health access. This can involve collecting data on key indicators over time and comparing them to the projected outcomes from the simulation.

By following this methodology, policymakers and healthcare stakeholders can make informed decisions about which innovations to prioritize and implement to improve access to maternal health.

Yabelana ngalokhu:
Facebook
Twitter
LinkedIn
WhatsApp
Email